Caribou Biosciences, Inc. Picked Up Intellia Therapeutics Inc. (NASDAQ:NTLA) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Intellia Therapeutics Inc. (NASDAQ:NTLA) reported that Caribou Biosciences, Inc. has picked up 5,593,846 of common stock as of 2017-02-28.

The acquisition brings the aggregate amount owned by Caribou Biosciences, Inc. to a total of 5,593,846  representing a 15.5% stake in the company.

For those not familiar with the company, Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

A glance at Intellia Therapeutics Inc(NASDAQ:NTLA)’s key stats reveals a current market capitalization of 562.27 million based on 36.00 million shares outstanding and a price at last close of $14.28 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-05-11, Orbimed picked up 58,534 at a purchase price of $18.00. This brings their total holding to 2,662,180 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Intellia Therapeutics Inc. (NASDAQ:NTLA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

Amyris Inc. (NASDAQ:AMRS) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Amyris Inc. (NASDAQ:AMRS) reported that Temasek Holdings (private) Ltd. has picked up 61,764,891 of common stock as of 2017-02-27.

The acquisition brings the aggregate amount owned by Temasek Holdings (private) Ltd. to a total of 61,764,891 representing a 22.1% stake in the company.

For those not familiar with the company, Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

A glance at Amyris Inc. (NASDAQ:AMRS)’s key stats reveals a current market capitalization of 140.76  million based on 273.83 Million shares outstanding and a price at last close of $0.523 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-06-14, Doerr picked up 200,577 at a purchase price of $1.04. This brings their total holding to 13,037,586 as of the date of the filing.

On the sell side, the most recent transaction saw Maxwell unload 254,570 shares at a sale price of $0.54. This brings their total holding to 56,812,277.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Amyris Inc. (NASDAQ:AMRS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

Biotechnology Value Fund is Buying Xoma Corp (NASDAQ:XOMA) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Xoma Corp (NASDAQ:XOMA) reported that Biotechnology Value Fund L P has picked up 695,726 of common stock as of 2017-02-21.

The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 695,726 representing a 9.2% stake in the company.

For those not familiar with the company, XOMA Corporation (NASDAQ:XOMA) is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

A glance at Xoma Corp (NASDAQ:XOMA)’s key stats reveals a current market capitalization of 39.56 million based on 7.52 million shares outstanding and a price at last close of $5.16 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2013-08-19, Baker picked up 21,410 at a purchase price of $3.62. This brings their total holding to 510,449 as of the date of the filing.

On the sell side, the most recent transaction saw Neal unload 95 shares at a sale price of $4.50. This brings their total holding to 20,471.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Xoma Corp (NASDAQ:XOMA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:EXEL) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Exelixis Inc. (NASDAQ:EXEL) reported that 1globe Capital Llc. has picked up 5,437,285 of common stock as of 2017-02-15.

The acquisition brings the aggregate amount owned by 1globe Capital Llc. to a total of 5,437,285 representing a 1.9% stake in the company.

For those not familiar with the company, Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

A glance at Exelixis Inc. (NASDAQ:EXEL)’s key stats reveals a current market capitalization of 6.08 billion based on 286.46 million shares outstanding and a price at last close of $22.02 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-05-11, Willsey picked up 20,000 at a purchase price of $4.95. This brings their total holding to 568,273 as of the date of the filing.

On the sell side, the most recent transaction saw Lamb unload 70,000 shares at a sale price of $18.65. This brings their total holding to 73,600.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Exelixis Inc. (NASDAQ:EXEL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

Vaccinogen Inc. (OTCMKTS:VGEN) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vaccinogen Inc. (OTCMKTS:VGEN) reported that Mpm Bioventures Iii L.p. has picked up 134,452 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Mpm Bioventures Iii L.p. to a total of 134,452 representing a 0.4% stake in the company.

For those not familiar with the company, Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient’s own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.

A glance at Vaccinogen Inc. (OTCMKTS:VGEN)’s key stats reveals a current market capitalization of 7.24 million based on 37.32 million shares outstanding and a price at last close of 0.169 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-12-26, Halldin picked up 934,580 at a purchase price of $5.50. This brings their total holding to 934,580 as of the date of the filing.

On the sell side, the most recent transaction saw Hanna unload 1,000 shares at a sale price of $3.61. This brings their total holding to 224,587.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vaccinogen Inc (OTCMKTS:VGEN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

Primecap Management Co/ca/ Picked Up Accuray Inc. (NASDAQ:ARAY) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Accuray Inc. (NASDAQ:ARAY) reported that Primecap Management Co/ca/ has picked up 5,513,300 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Primecap Management Co/ca/ to a total of 5,513,300 representing a 6.75% stake in the company.

For those not familiar with the company, Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

A glance at Accuray Inc. (NASDAQ:ARAY)’s key stats reveals a current market capitalization of 455.94 million based on 82.90 million shares outstanding and a price at last close of $5.50 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-11-9, Levine picked up 50,000 at a purchase price of $7.12. This brings their total holding to 1,115,830 as of the date of the filing.

On the sell side, the most recent transaction saw Nouri unload 957 shares at a sale price of $6.80. This brings their total holding to 65,547.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Accuray Inc. (NASDAQ:ARAY) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

OrbiMed Advisors is Buying Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported that OrbiMed Advisors has picked up 2,524,000 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by OrbiMed Advisors to a total of 2,524,000 representing a 1.73% stake in the company.

For those not familiar with the company, Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

A glance at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)’s key stats reveals a current market capitalization of 2.41 billion based on 130.86 million shares outstanding and a price at last close of $16.42 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2011-11-02, Hecht picked up 50,000 at a purchase price of $11.65. This brings their total holding to 72,803 as of the date of the filing.

On the sell side, the most recent transaction saw Hecht unload 32,994 shares at a sale price of $15.50. This brings their total holding to 4,670,322.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

Guess Who Picked Up Integra Lifesciences Holdings Corp. (NASDAQ:IART) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Integra Lifesciences Holdings Corp. (NASDAQ:IART) reported that Caruso Richard E. has picked up 6,201,027 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Caruso Richard E. to a total of 6,201,027 representing a 16.57% stake in the company.

For those not familiar with the company, Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.

A glance at Integra Lifesciences Holdings Corp (NASDAQ:IART)’s key stats reveals a current market capitalization of 3.20 billion based on 74.77 million shares outstanding and a price at last close of $42.90 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2011-11-02, Caruso picked up 2,000 at a purchase price of $28.46. This brings their total holding to 2,000 as of the date of the filing.

On the sell side, the most recent transaction saw Arduini unload 20,000 shares at a sale price of $80.02. This brings their total holding to 25,593.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Integra Lifesciences Holdings Corp. (NASDAQ:IART) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

Skip to content